| reference | Supko, J.G., et al., Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 36, 305-315, (1995) |
| | Chavany, C., et al., p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J. Biol. Chem. 271, 4974, (1996) |
| | Whitesell, L., et al., Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol. Endocrinol. 10, 705-712, (1996) |
| | Stebbins, C.E., et al., Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89, 239-250, (1997) |
| | Whitesell, L., et al., Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. U. S. A. 91, 8324-8328, (1994) |
| | Schneider, C., et al., Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl. Acad. Sci. U. S. A. 93, 14536-14541, (1996) |
| | Joly, G.A., et al., Potent inhibition of inducible nitric oxide synthase by geldanamycin; a tyrosine kinase inhibitor in endothelial smooth muscle cells and in rat aorta. FEBS Lett., 40, (1997) |
